Feasibilty and Acceptability of Amani
ConditionSickle Cell Disease
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMassachusetts General Hospital
About this trial
Adults with sickle cell disease (SCD) experience severe pain, emotional distress, and social isolation that diminish their quality of life. This project will test Amani, a novel virtual reality supportive care intervention designed to improve coping skills and strengthen peer support. If feasible and acceptable, Amani offers an accessible digital supportive care intervention to improve psychological well-being and quality of life among individuals living with SCD and potentially other chronic illnesses.
Eligibility criteria
Qualifiers
Adults (≥ 18 years) who are diagnosed with sickle cell disease
Primarily followed at the Massachusetts General Hospital (MGH) Sickle Cell Disease Center
Have ability to comprehend and speak English given Amani is currently only available in English.
Disqualifiers
Have severe psychiatric (psychotic disorder, bipoloar disorder) or cognitive impairment which the treating hematologist believes would preclude ability to participate in the clinical trial
Trial design
Treatments tested in this trial
- Amani
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Ascent
Collaborator
Source ClinicalTrials.gov